Table 1 Individual studies characterization
ID | Author | Year of study publication | Type of study | Study population origin (country) | Cohort origin | Sample type | Age (range) | Number of samples | Number of CIN2+ (%) | Number of CIN3+ (%) | DNA methylation markers studied | Panel versus single versus both | Platform | Pre-established cutoff yes/no/unclear | Refs. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Studies with health professional-collected samples | |||||||||||||||
L1 | Bonde a | 2021 | Convenience1 | Scotland | PAVDAG | Cervical scrape | 30–61 | 161 | 40 (24.8%) | 25 (15.5%) | FAM19A4/miR124-2 | Panel | QMSP | Yes | [13] |
Bonde b | Denmark | VALGENT4 + routine screening | 30–65 | 424 | 75 (17.7%) | 57 (13.4%) | |||||||||
Bonde c | Slovenia | Routine screening | 30–76.3 | 928 | 102 (11.0%) | 60 (6.5%) | |||||||||
Bonde d | The Netherlands | VUSA screen | 29–61 | 871 | 155 (17.8%) | 106 (12.2%) | |||||||||
B1 | Hesselink | 2011 | Convenience1 | The Netherlands | Routine screening | Cervical scrape | 19–62 | 236 | 58 (24.6%) | 38 (16.1%) | CADM1/MAL | Panel | QMSP | Yes | [12] |
F5 | Verhoef | 2015 | Referral population based | The Netherlands | PROHTECT-3 (Cytology arm) | Cervical scrape | 38–48 | 364 | 90 (24.7%) | 62 (17.0%) | CADM1/MAL | Panel | QMSP | Yes | [20] |
L2 | Vink | 2021 | Referral population based | The Netherlands | POBASCAM | Cervical scrape | 26–61 | 979 | – | 115 (11.7%) | FAM19A4/miR124-2 | Panel | QMSP | Yes | [23] |
F1 | Vuyst | 2015 | Cohort | Kenya | HIV-infected | Cervical scrape | 18–55 | 248 | 93 (37.5%) | – | CADM1/MAL/miR124-2 | Panel | QMSP | No | [33] |
I1 | Bu | 2018 | Cohort | China | Routine screening | Cervical scrape | – | 215 | 118 (54.9%) | – | FAM19A4 | Single | QMSP | No | [28] |
E4 | De Strooper | 2014 | Cohort | The Netherlands | Routine screening | Cervical scrape | 19–62 | 218 | 52 (23.9%) | 33 (15.1%) | FAM19A4 | Single | QMSP | Yes | [17] |
G4 | Luttmer | 2016 | Referral population based | The Netherlands | COMETH | Cervical scrape | 18–70 | 508 | 180 (35.4%) | 90 (17.7%) | FAM19A4 | Single | QMSP | Yes | [18] |
J1 | Cook | 2019 | Case–control | Canada | FOCAL | Cervical scrape | 25–65 | 257 | 107 (41.6%) | 44 (17.1%) | S5 (EPB41L3/HPV16L1/HPV16L2/HPV18L2/HPV31L1/HPV33L2) | Panel | QMSP | Yes | [34] |
G2 | Lorincz | 2016 | Case–control | United Kingdom | Predictors 3 (P3) | Cervical scrape | – | 341 | 39 (11.4%) | – | S5 (EPB41L3/HPV16L1/HPV16L2/HPV18L2/HPV31L1/HPV33L2) and S4 (EPB41L3/HPV16L1/HPV16L2/HPV18L2/HPV31L1) | Panel | Pyrosequencing | Yes | [25] |
E1 | Boers | 2014 | Convenience1 | The Netherlands | PROHTECT-3B | Cervical scrape | 33–67 | 128 | 49 (38.3%) | 34 (26.6%) | C13ORF18/EPB41L3/JAM3/TERT | Single | QMSP | No | [16] |
K3 | Li | 2020 | Cohorts | Chinese | Outpatient clinic population | Cervical scrape | 18–67 | 227 | 129 (56.8%) | 83 (36.6%) | ANKRD18CP/C13orf18/EPB41L3/JAM3/SOX1/ZCAN1 | Both | QMSP | Yes | [29] |
J7 | van Leeuwen | 2019 | Referral population based | Slovenian | Slovenian HPV Prevalence Study | Cervical scrape | – | 235 | 35 (14.9%) | 19 (8.1%) | ANKRD18CP/ C13orf18/EPB41L3/ JAM3/SOX1/ZCAN1 | Both | QMSP | Yes | [27] |
H7 | Yuan | 2017 | Case–control | China | Hospital-based study | Cervical scrape | – | 259 | 164 (63.3%) | 118 (45.6%) | C13ORF18/JAM3/ SLIT2/SOX1/TERT | Both | Pyrosequencing | Unclear | [32] |
F6 | Yin | 2015 | Cohort | China | Outpatient clinic population | Cervical scrape | – | 168 | 72 (42.9%) | 31 (18.5%) | JAM3 | Single | QMSP | No | [31] |
E5 | Hansel | 2014 | Cohort | Germany | Outpatient clinic population | Cervical scrape | 18–81 | 217 | 84 (38.7%) | 42 (19.4%) | DLX1/ITGA4/RXFP3/SOX17/ZNF671 | Panel | QMSP | No | [24] |
H4 | Schmitz | 2017 | Cohort | Germany | Outpatient clinic population | Cervical scrape | – | 189 | –- | 89 (47.1%) | ASTN1/DLX1/ITGA4/RXFP3/SOX17/ ZNF671 | Panel | QMSP | Yes | [26] |
H5 | Tian | 2017 | Cohort | China | Outpatient clinic population | Cervical scrape | – | 312 | –- | 155 (49.7%) | ZNF582/PAX1 | Both2 | QMSP | Yes | [30] |
Studies with self-collected samples | |||||||||||||||
G1 | De Strooper a | 2016 | Referral population based | The Netherlands | PROHTECT-3A | Self-collected cervico-vaginal lavage | 33–63 | 389 | 119 (30.6%) | 78 (20.1%) | FAM19A4/miR124-2 | Panel | QMSP | Yes | [14] |
De Strooper b | 2016 | The Netherlands | PROHTECT-2 | Self-collected vaginal brush | 30–62 | 254 | 99 (39.0%) | 72 (28.3%) | |||||||
E10 | Verhoef | 2014 | Referral population based | The Netherlands | PROHTECT-3 (methylation arm) | Self-collected cervico-vaginal lavage | 30–60 | 408 | 124 (30.4%) | 79 (19.4%) | MAL/miR124-2 | Panel | QMSP | Yes | [21] |
E9 | Verhoef | 2014 | Referral population based | The Netherlands | PROHTECT-3 | Self-collected cervico-vaginal lavage | 30–64 | 1019 | 225 (22.1%) | 147 (14.4%) | MAL/miR124-2 | Panel | QMSP | Yes | [22] |
G3 | Luttmer | 2016 | Referral population based | The Netherlands | COMETH | Self-collected cervico-vaginal lavage | 18–66 | 450 | 153 (34.0%) | 75 (16.7%) | FAM19A4 | Single | QMSP | Yes | [19] |
I8 | Verlaata | 2018 | Convenience1 | The Netherlands | PROHTECT-3B | Self-collected vaginal brush | 27–75 | 287 | 109 (38.0%) | 81 (28.2%) | ASCL1/LHX8/ ST6GALNAC5 | Panel | QMSP | Yes | [15] |
Verlaatb | 2018 | The Netherlands | PROHTECT-3 | Self-collected cervico-vaginal lavage | 33–63 | 199 | 65 (32.7%) | 43 (21.6%) | |||||||